Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-05-01
|
Series: | Signal Transduction and Targeted Therapy |
Online Access: | https://doi.org/10.1038/s41392-021-00628-x |